大剂量甲泼尼龙和大剂量丙种球蛋白冲击治疗成人重症特发性血小板减少性紫癜短期疗效评估(2)
 |
| 第1页 |
参见附件(1237KB，2页)。
由此可见,HDMP短程治疗成人重症ITP疗效同HDIVIG,能迅速提升血小板于相对安全范围,无明显副作用,然而相对HDIVIG,HDMP费用较低,因此适宜临床广泛使用。
参 考 文 献
[1] 张之南,沈递.血液病诊断及疗效标准.北京:科学出版社,2007:172-176.
[2] Demircio lu F, Saygi M, Yilmaz S,et al. Clinical features, treatment responses, and outcome of children with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol, 2009,26(7):526-532.
[3] Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura:a randomised, multicentre trial. Lancet,2002,359(9300):23-29.
[4] 李绪香.大剂量甲基强的松龙与静脉输注免疫球蛋白治疗急性血小板减少性紫癜临床观察.中国医药导报,2006,3(35):69-70.
[5] Benesch M, Kerbl R, Lackner H, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol, 2003,25(10):797-800.
[6] Yetgin S, Yenicesu IC, Ersoy F. The effects of megadose methylprednisolone therapy on the immune system in childhood immune thrombocytopenia. Pediatr Hematol Oncol, 2005,22(5):401-407.
您现在查看是摘要介绍页，详见PDF附件(1237KB，2页)。